Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 6/20 | 0.63 |
| ▸ | ELANE | P08246 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LSS | P48449 | 1/20 | 0.53 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | TOP2A | P11388 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5757366 | 0.94 | ELANE (0.58) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL5757982 | 0.93 | ELANE (0.57) | TP53ELANEMAPTKLKB1HPGD | |
| SCHEMBL5756699 | 0.93 | ELANE (0.57) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL6212506 | 0.92 | TP53 (0.55) | TP53ELANEMAPTKLKB1HPGD | |
| SCHEMBL5758434 | 0.92 | ELANE (0.56) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL5757268 | 0.91 | TP53 (0.57) | TP53ELANEMAPTLSSHPGD | |
| SCHEMBL5758118 | 0.90 | ELANE (0.75) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL5755885 | 0.89 | ELANE (0.54) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL5759600 | 0.88 | KDM4E (0.55) | TP53ELANEMAPTLSSKLKB1 | |
| SCHEMBL5757167 | 0.88 | MAPT (0.53) | TP53ELANEMAPTHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1562902-B1 | 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE | ASTRAZENECA AB (SE) | 2006-05-03 | — | — | EP | disclosed |
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | ASRAZENECA AB (SE) | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035938-A1 | 2-Pyridone derivatives as inhibitors of neutrophile elastase | SERPINB1, ELANE, SERPINE1 | TP53 3353/4885ELANE 2/4885MAPT 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.